

Program Book



**Dermato-
Onco2024**

The European Congress on
Dermato-Oncology

31 October - 1 November 2024
Vienna, Austria



Bio events
Sharing Biomed Knowledge

Join the conversation and feel free to tag
#DermatoOnco2024



Congress Venue

Doubletree by Hilton Vienna Schönbrunn

Schlossallee 8, 1140 Vienna, Austria

Tel: +43 1 89110

Congress Hours

The Registration Desk will be open during the following times:

Thursday, 31 October 08:00-17:15

Friday, 1 November 08:30-17:10

Participants Badge

Upon registration, you will receive your name badge. You are kindly requested to wear your name badge throughout the Congress.

Refreshments

Coffee and lunch will be served in the Foyer at the times indicated in the Congress Timetable.

Congress Abstracts

The accepted abstracts of **Dermato-Oncology2024** are available online at www.dermato-oncology2024.com

Safety and Security

Please do not leave any bags or suitcases unattended at any time, whether inside or outside session halls. The Congress Organizers cannot accept liability for personal accidents or loss of/damage to private property of participants of **Dermato-Oncology2024**.

Congress Secretariat: info@bioevents-congress.com

Tel: US +1-857-400-0035 ; UK +44-203-051-4032

Thursday, 31 October 2024

08:00-17:15 Registration

09:00-09:10

Welcome & Opening Remarks

Alexander M.M. Eggermont, Netherlands | Congress Chair

Mario Mandalà, Italy | Congress Chair

Session 1: Keynote Lectures

Chairs: Alexander M.M. Eggermont, Netherlands

Mario Mandalà, Italy

09:10-09:40

Keynote Lecture 1: Artificial Intelligence in Melanoma and Other Skin Cancer Diagnosis

Harald Kittler, Medical University of Vienna, Austria

09:40-09:45

Discussion/Q&A

09:45-10:15

Keynote Lecture 2: New Developments/New Drugs and Strategies in Targeted therapies for Melanoma and NMSC

Reinhard Dummer, University Hospital of Zürich, Switzerland

10:15-10:20

Discussion/Q&A

10:20-10:50

Keynote Lecture 3: Personalized versus non-personalized vaccines

Reinhard Dummer, University Hospital of Zürich, Switzerland

10:50-10:55

Discussion/Q&A

10:55-11:25 Coffee Break, Poster Viewing & Visit the Exhibition

Session 2: Short Presentations by Young Investigators

Chair: Alexander M.M. Eggermont, Netherlands

11:25-11:35

Circulating Tumor DNA (ctDNA) in Stage-III BRAF+ Patients: a Real-life Study in the Adjuvant Setting

Gabriele Rocuzzo, Sara Marchisio, Alessia Andrea Ricci, Eleonora Bongiovanni, Erika Ortolan, Luca Bertero, Enrico Berrino, Valentina Pala, Renata Ponti, Paolo Fava, Simona Osella Abate, Silvia Deaglio, Caterina Marchiò, Anna Sapino, Rebecca Senetta, Ada Funaro, Simone Ribero, Paola Cassoni, Pietro Quaglino, Italy

11:35-11:45

Development of a Deep Learning Model for Histopathological Prognostication of Localised Melanoma

Tom Andrew, Phil Sloan, Marc Combalia, Carlos Hernandez, Aidan Rose, Penny Lovat, United Kingdom

11:45-11:55

Genomic Mechanisms of Aggressive and metastatic Phenotypes in Non-Melanoma Skin Cancers

Andrey Yurchenko, Andrea Forschner, Fatemeh Rajabi, Oltin Pop, Laurent Parmentier, Denis Salomon, Lukas Flatz, Sergey Nikolaev, France



Your partner in dermato-oncology

Sun Pharma is a global Pharmaceutical company with its Western European Headquarters based near Amsterdam (The Netherlands).

Committed to continuous innovation in the dermato-oncology field, and after 7 successful years of activity in laBCC, Sun Pharma is ready to address medical unmet needs in melanoma.

11:55-12:00 **Discussion/Q&A**

12:00-12:30 **Industry Symposium | Sponsored by MSD**

12:00-12:05 **Welcome and Introductions**

Reinhard Dummer, University Hospital Zurich, Switzerland

12:05-12:15 **Any Prognostic Biomarkers Ready for Use in Early-Stage Melanoma Patients?**

Teresa Amaral, University Hospital Tübingen, Germany

Reinhard Dummer, University Hospital Zurich, Switzerland

12:15-12:25 **Why I Do (not) Treat Early-Stage Melanoma?**

Reinhard Dummer, University Hospital Zurich, Switzerland

Teresa Amaral, University Hospital Tübingen, Germany

12:25-12:30 **Q&A/Panel Discussion**

12:30-13:30 Lunch Break, Poster Viewing & Visit the Exhibition

Session 3: Keynote Lecture

Chair: Mario Mandalà, Italy

13:30-13:55 **Keynote Lecture 4: Prevention of Skin Cancers:
Fact or Fiction, Limitations vs Opportunities**

Philippe Autier, International Prevention Research Institute, France

13:55-14:00 **Discussion/Q&A**

Session 4: Melanoma Staging under Scrutiny, Current & Future Developments

Chair: Teresa Amaral, Germany

14:00-14:25 **Sentinel Lymph Node Risk Prognostication in Primary Cutaneous Melanoma Through Tissue-based Profiling, Potentially Redefining the Need for Sentinel Lymph Node Biopsy**

Julian Kött, University Medical Center Hamburg, Germany

14:25-14:50 **CP-GEP as a Tool to Identify Risk of Relapse in Stage I/II and Head & Neck Melanoma Populations**

Teresa Amaral, University Hospital Tübingen, Germany

14:50-15:00 **Discussion/Q&A**

15:00-15:30 Coffee Break, Poster Viewing & Visit the Exhibition

Session 5: What is New in Rare Malignancies

Chair: Mario Mandalà, Italy

15:30-15:55 **What's New in Merkel Cell Carcinoma?**

Jürgen Becker, German Cancer Research Center (DKFZ), Germany

REGENERON

SCIENCE TO MEDICINE®



15:55-16:20 **What's New in Uveal Melanoma?**
Paul Nathan, Mount Vernon Cancer Centre, UK

16:20-16:45 **Melanoma in Children and Young Adults**
Mario Mandalà, University of Perugia, Santa Maria Misericordia Perugia, Italy

Session 6: Keynote Lecture

Chair: Alexander M.M. Eggermont, Netherlands

16:45-17:15 **Keynote Lecture 5: Microbiome and Immunotherapy**
Laurence Zitvogel, Gustave Roussy Cancer Campus, France

17:15 **End of Day One**

Friday, 1 November 2024

08:30-17:10 **Registration**

Session 7: Adjuvant and Neoadjuvant Therapy in Dermato-Oncology

Chair: Alexander M.M. Eggermont, Netherlands

09:00-09:25 **Adjuvant Therapy of Melanoma and the Role for Identifiers of High Risk for Relapse: Consequences for New Trials and Daily Practice**
Alexander M.M. Eggermont, Utrecht University, Netherland

09:25-09:50 **Neoadjuvant Immunotherapy the Standard for Stage III and Beyond?**
Christian Blank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Netherlands

09:50-10:15 **Reducing Surgical Interventions in Melanoma Management**
Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Poland

10:15-10:40 **Neoadjuvant or Adjuvant Therapy in NMSC for Which Populations?**
C.L. (Lotje) Zuur, Netherlands Cancer Institute Antoni van Leeuwenhoek, Netherlands

10:40-11:00 **Coffee Break, Poster Viewing & Visit the Exhibition**

Session 8: Keynote Lectures

Chair: Alexander M.M. Eggermont, Netherlands

11:00-11:30 **Keynote Lecture 6: New Vaccines for Melanoma: What is New and Most Promising?**
Olivier Michielin, University Hospital Geneva, Switzerland

11:30-11:35 **Discussion/Q&A**

11:35-12:05 **Keynote Lecture 7: Precision Immuno-Oncology:
What are the Complexities and Promises**
Olivier Michelin, University Hospital Geneva, Switzerland

12:05-12:10 **Discussion/Q&A**

Session 9: Prediction, Registration and Management of irAEs *Chair: Mario Mandalà, Italy*

12:10-12:35 **Immune Signatures Predict Development of Autoimmune
Toxicity in Patients with Cancer Treated with Immune
Checkpoint Inhibitors**
Lukas Flatz, University Hospital Tübingen, Germany

12:35-13:00 **The New WHO Pathology Classification of Melanoma:
Pros and Cons**
Daniela Massi, University of Florence, Italy

13:00-14:00 **Lunch Break, Poster Viewing & Visit the Exhibition**

Industry Spotlight | Sponsored by Sanofi

14:00-14:10 **Skin Toxicities from Immune Checkpoint Blockade**
*Yevgeniy (Eugene) R. Semenov, Massachusetts General Hospital, Harvard
Medical School, USA*

Session 10: New Strategies in Advanced Melanoma *Chair: Alexander M.M. Eggermont, Netherlands*

14:10-14:35 **Prevention and Screening of Melanoma in Europe:
20 Years of the Euromelanoma Campaign**
*Veronique del Marmol, Hospital HUB (Hopital Erasme-Institut Jules Bordet),
Université Libre de Bruxelles, Belgium*

14:35-15:00 **Current and Future Treatment Options for Brain
Metastases**
Anna Maria Di Giacomo, University of Siena, Italy

15:00-15:25 **From IO Doublet Combos to Triplet Combos
in Immunotherapy of Advanced Melanoma**
*Christian Blank, Netherlands Cancer Institute -
Antoni van Leeuwenhoek Hospital, Netherlands*

15:25-15:30 **Discussion/Q&A**

15:30-16:00 **Coffee Break, Poster Viewing & Visit the Exhibition**

Session 11: Short Presentations by Young Investigators

Chair: Mario Mandalà, Italy

- 16:00-16:10 **Artificial Ultraviolet Radiation and Skin Melanoma in Iceland and the Faroe Islands**
Astrid Coste, Brian Koster, Jean-François Doré, Philippe Autier, France
- 16:10-16:20 **Skin Cancer Risk in over 200.000 Patients with Hematologic Malignancies in 30 Years; a Nationwide, Population-based Study in the Netherlands**
Celeste Eggermont, Andrya Hollatz, Marlies Wakkee, Marieke Louwman, Avinash Dinmohamed, Eduardus Posthuma, Tamar Nijsten, Loes Hollestein, Netherlands
- 16:20-16:30 **Clinical Use of the i31-GEP for SLNB for T1-T2a Cutaneous Melanoma Significantly and Safely Reduces Unnecessary Procedures**
Timothy Beard, Stanley P. Leong, Rajan P. Kulkarni, Brian Martin, Kelli Ahmed, Andrew Ward, J. Michael Guenther, Shawn Young, USA
- 16:30-16:40 **Diagnosing and Guiding Non-Surgical Therapy of Basal Cell Carcinoma with Combined Optical Coherence Tomography/Reflectance Confocal Microscopy**
Nicusor Iftimia, Milind Rajadhyaksha, Aditi Sahu, Miguel Cordova, Gopi Maguluri, John Grimble, Cristopher Barker, Chih-Shan J. Chen, USA
- 16:40-16:50 **Retrospective Real-Life Evaluation of Outcome after Discontinuation of anti-PD1 Therapy for Complete Response Cutaneous Squamous Cell Carcinoma in Patients over 75 Years of Age**
Julie Lardenois, Marie Boileau, Eve Desmedt, Marie Bridoux, Sophie Maiezza, Laurent Mortier, France
- 16:50-17:00 **Neoadjuvant Atezolizumab in Patients with Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma**
Vasu Divi, Sumaira Aasi, Saad Khan, Lily Lam, Luis Martinez Ramirez, John Sunwoo, Mobeen Rahman, Yifei Ma, Fred Baik, Michelle Chen, Andrey Finegersh, Kelsey Hirotsu, Chris Holsinger, Nour Kibbe, Davud Sirjani, Nikita Bedi, Harlan Pinto, Dimitrios Colevas, USA
- 17:00-17:10 **Poster Award Ceremony / Conclusions and Closure**
Prof. Dr. Alexander M.M. Eggermont, Netherlands
Dr. Mario Mandalà, Italy | Congress Chairs
- 17:10 **End of Congress**

Posters will be on display for the duration of the Congress.

Posters may be mounted from 08:00 AM on Thursday, 31 October and should be removed by the end of sessions on Friday, 1 November. The Congress Organizers cannot be responsible for posters not removed by this time.

Please hang your poster on the poster board assigned to you.

| Board # | Abstract Title |
|---------|---|
| 01 | In vitro Evaluation of the Efficacy of Rose Bengal Photodynamic Therapy in Human Melanoma <i>Marie Boileau, Smail Marhfor, Anthony Lefebvre, Olivier Morales, Nadira Delhem, Laurent Mortier, France</i> |
| 02 | Comparative Outcomes of Nodal Dissection Versus Observation in Stage-III Melanoma Patients with Positive Sentinel Lymph-node Biopsy: A Real-life Study Using Inverse Probability of Treatment Weighting <i>Gabriele Rocuzzo, Nicole Macagno, Pietro Grignani, Chiara Astrua, Matteo Brizio, Franco Picciotto, Virginia Caliendo, Enrico Fruttero, Simone Ribero, Paolo Fava, Italy</i> |
| 03 | Vulvar Melanoma with Vaginal Recurrence: A Case Study <i>Kristin Walker, Daniel Leach, Yhana Chavis, Kari Ring, Elizabeth Gaughan, Einsley Janowski, Kara Romano, USA</i> |
| 04 | Acute Immuno-Induced Meningoradiculitis Leading to Patient Death <i>Juliette DEUZE, Marie Boileau, Bruno Lemarchand, Céline Yelnik, Eve Desmedt, Laurent Mortier, France</i> |
| 05 | The Definitive Treatment of Facial Lentigo Maligna with Tomotherapy-based Radiotherapy. The Experience of Centro di Riferimento Oncologico (CRO) di Aviano <i>Giuseppe Fanetti, Paola Corsetti, Giuseppe Anastasio, Valentina Lupato, Paola Pase, Lisa Andreon, Federica Bertini, Manuele Roghi, Jerry Polesel, Paola Chiovati, Vittorio Giacomarra, Maurizio Mascarin, Maria Antonietta Pizzichetta, Italy</i> |
| 06 | PAGETEX Photodynamic Therapy Device for the Treatment of Extra Mammary Vulvar Paget's Disease: Interim Analysis of Safety Data <i>Marie Boileau, Anne Sophie Dewalle, Henry Abi Rached, Gregory Baert, Shirley Balik, Nadira Delhem, Cyril Maire, Laurent Mortier, France</i> |
| 07 | Primary Cutaneous B-cell Lymphoma: A Case Report <i>Sidita Borici, Albania</i> |

| | |
|----|--|
| 08 | <p>Genomic Mechanisms of Aggressive and Metastatic Phenotypes in Non-Melanoma Skin Cancers</p> <p>Andrey Yurchenko, Andrea Forschner, Oltin Pop, Laurent Parmentier, Denis Salomon, Lukas Flatz, Sergey Nikolaev, France</p> |
| 09 | <p>Chondroitin Sulfate Proteoglycan 4 as a Driver of Malignancy in Aggressive Squamous Cell Carcinoma with a Focus on Epidermolysis Bullosa</p> <p>Jasmine Mingjie Zhou, Kathryn Chen, Chen Wang, Jessica Sydney Ramos, Fiaz Chowdhury, Verena Wally, Roland Zauner, Josefina Pinon Hofbauer, Kang Liang, Kieran S Scott, Paul De Souza, Fred Azimi, Albert S Mellick, Australia</p> |
| 10 | <p>Development of a Deep Learning Model for Histopathological Prognostication of Localised Melanoma</p> <p>Tom Andrew, Phil Sloan, Marc Combalia, Carlos Hernandez, Aidan Rose, Penny Lovat, United Kingdom</p> |
| 11 | <p>Diagnosing and Guiding Non-Surgical Therapy of Basal Cell Carcinoma with Combined Optical Coherence Tomography/ Reflectance Confocal Microscopy</p> <p>Nicusor Iftimia, Milind Rajadhyaksha, Aditi Sahu, Miguel Cordova, Gopi Maguluri, John Grimble, Cristopher Barker, Chih-Shan J. Chen, USA</p> |
| 12 | <p>Reducing the Diagnostic Delay Between Tele-Expertise and Conventional Referral in the Management of Suspicious Lesions</p> <p>Ines Belkasm, Selma Azib, Eve Desmedt, Sophie Maiezza, Laurent Mortier, Marie Boileau, France</p> |
| 13 | <p>Desmoplastic Melanoma as a Clinical and Therapeutic Challenge</p> <p>Sidita Borici, Albania</p> |
| 14 | <p>Artificial Ultraviolet Radiation and Skin Melanoma in Iceland and the Faroe Islands</p> <p>Astrid Coste, Brian Koster, Jean-François Doré, Philippe Autier, France</p> |
| 15 | <p>Skin Cancer Risk in over 200.000 Patients with Hematologic Malignancies in 30 Years; a Nationwide, Population-based Study in the Netherlands</p> <p>Celeste Eggermont, Andrya Hollatz, Marlies Wakkee, Marieke Louwman, Avinash Dinmohamed, Eduardus Posthuma, Tamar Nijsten, Loes Hollestein, Netherlands</p> |
| 16 | <p>Clinical Use of the i31-GEP for SLNB for T1-T2a Cutaneous Melanoma Significantly and Safely Reduces Unnecessary Procedures</p> <p>Timothy Beard, Stanley P. Leong, Rajan P. Kulkarni, Brian Martin, Kelli Ahmed, Andrew Ward, J. Michael Guenther, Shawn Young, USA</p> |

| | |
|----|---|
| 17 | <p>The Possibilities of Electrophoton Emission Analysis in the Medical Examination of dysplastic nevi <i>Stanislav Panov, Nurlan Baltabekov, Daut Makanov, Kazakhstan</i></p> |
| 18 | <p>Circulating Tumor DNA (ctDNA) in Stage-III BRAF+ Patients: a Real-life Study in the Adjuvant Setting <i>Gabriele Rocuzzo, Sara Marchisio, Alessia Andrea Ricci, Eleonora Bongiovanni, Erika Ortolan, Luca Bertero, Enrico Berrino, Valentina Pala, Renata Ponti, Paolo Fava, Simona Osella Abate, Silvia Deaglio, Caterina Marchiò, Anna Sapino, Rebecca Senetta, Ada Funaro, Simone Ribero, Paola Cassoni, Pietro Quaglino, Italy</i></p> |
| 19 | <p>Genomic Analysis of Skin Cancers from Xeroderma Pigmentosum Subgroups Revealed New Mechanisms of UV Mutagenesis <i>Sergey Nikolaev, Andrey Yurchenko, Fatemeh Rajabi, Tirzah Lajus, Hiva Fassihi, Konstantin Gunbin, Ismael Padioleau, Chikako Nishigori, Patricia Kannouche, Carlos Menck, Alain Lehmann, Alain Sarasin, France</i></p> |
| 20 | <p>cdNA Recombinant Proteins for Dermatological and Cosmetic Protection: Use of Synthetic Biology <i>Raul Cuero, Ph.D, USA</i></p> |
| 21 | <p>Selling Sunbeds <i>Amy Long, Karen Eustace, Ireland</i></p> |
| 22 | <p>Therapy Sequencing in BRAF-Mutant Metastatic Melanoma, a Case Report <i>Luca Ambrus, Tímea Balatoni, Kata Czirbesz, Mihály Tamás Kispál, Hungary</i></p> |
| 23 | <p>Retrospective Real-life Evaluation of Outcome after Discontinuation of anti-PD1 Therapy for Complete Response Cutaneous Squamous Cell Carcinoma in Patients over 75 Years of Age <i>Julie Lardenois, Marie Boileau, Eve Desmedt, Marie Bridoux, Sophie Maiezza, Laurent Mortier, France</i></p> |
| 24 | <p>Neoadjuvant Atezolizumab in Patients with Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma <i>Vasu Divi, Sumaira Aasi, Saad Khan, Lily Lam, Luis Martinez Ramirez, John Sunwoo, Mobeen Rahman, Yifei Ma, Fred Baik, Michelle Chen, Andrey Finegersh, Kelsey Hirotsu, Chris Holsinger, Nour Kibbe, Davud Sirjani, Nikita Bedi, Harlan Pinto, Dimitrios Colevas, USA</i></p> |
| 25 | <p>A New Model of Dispensary, Rehabilitation and Immunosurveillance of Melanoma <i>Stanislav Panov, Nurlan Baltabekov, Kazakhstan</i></p> |

Dermato-Oncology2024 would like to express its gratitude and acknowledge the following companies and organizations for their support of the Congress.

Platinum Sponsor



Silver Sponsors

REGENERON[®]

sanofi | ***REGENERON***[®]

Bronze Sponsor





sanofi

REGENERON®

